InflaRx (IFRX)
(Delayed Data from NSDQ)
$1.53 USD
+0.02 (1.32%)
Updated Oct 2, 2024 04:00 PM ET
After-Market: $1.53 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
F Value F Growth D Momentum F VGM
Brokerage Reports
0 items in cart
InflaRx N.V. [IFRX]
Reports for Purchase
Showing records 1 - 20 ( 55 total )
Company: InflaRx N.V.
Industry: Medical - Biomedical and Genetics
2Q24 Results; Phase 3 Interim Analysis for Gohibic in Pyoderma Gangrenosum Expected in 2025
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: InflaRx N.V.
Industry: Medical - Biomedical and Genetics
Gohibic (vilobelimab) Selected for BARDA-Sponsored Trial Evaluating New Treatment Options for ARDS
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: InflaRx N.V.
Industry: Medical - Biomedical and Genetics
Company: InflaRx N.V.
Industry: Medical - Biomedical and Genetics
1Q24 Results; RD Day in June to Highlight Potential Development of INF904
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: InflaRx N.V.
Industry: Medical - Biomedical and Genetics
4Q23 Results; INF904 Development Plans Focused on Chronic Inflammatory Skin Conditions
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: InflaRx N.V.
Industry: Medical - Biomedical and Genetics
InflaRx Announces Launch of Commitment Program for Gohibic; Lowering PT Due to Lower Revenue Expectations
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: InflaRx N.V.
Industry: Medical - Biomedical and Genetics
Encouraging Topline Results From MAD Part of Phase 1 Study of INF904
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: InflaRx N.V.
Industry: Medical - Biomedical and Genetics
Company: InflaRx N.V.
Industry: Medical - Biomedical and Genetics
3Q23 Results; Gohibic Records First Commercial Sales
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: InflaRx N.V.
Industry: Medical - Biomedical and Genetics
Positive Results From Phase 1 Single Ascending Dose Study of INF904
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: InflaRx N.V.
Industry: Medical - Biomedical and Genetics
MAA for Gohibic (vilobelimab) in COVID-19 Validated and Under Review
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: InflaRx N.V.
Industry: Medical - Biomedical and Genetics
2Q23 Results; Gohibic in COVID-19 U.S. Commercial Launch Ongoing; cSCC Data Announced
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: InflaRx N.V.
Industry: Medical - Biomedical and Genetics
U.S. Commercial Launch of Gohibic for Critically Ill COVID-19 Patients
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: InflaRx N.V.
Industry: Medical - Biomedical and Genetics
1Q23 Results; First Gohibic Sales Expected 3Q23; Phase 3 Study in PG Anticipated to Start Mid-Year
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: InflaRx N.V.
Industry: Medical - Biomedical and Genetics
Model Update Following Capital Raise; Lowering PT by $1 Due to Dilution
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: InflaRx N.V.
Industry: Medical - Biomedical and Genetics
FDA Grants Emergency Use Authorization For Gohibic (vilobelimab) For the Treatment of Critically Ill COVID-19 Patients
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: InflaRx N.V.
Industry: Medical - Biomedical and Genetics
4Q22 Results; PG Phase 3 Trial to Enroll First Patient in Mid-23; Still Waiting for Potential EUA for COVID-19 Patients
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: InflaRx N.V.
Industry: Medical - Biomedical and Genetics
Update on Phase 3 Trial of Vilobelimab in Pyoderma Gangrenosum
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: InflaRx N.V.
Industry: Medical - Biomedical and Genetics
Company: InflaRx N.V.
Industry: Medical - Biomedical and Genetics
3Q22 Results; Vilobelimab for COVID-19 EUA Request Submitted to FDA in September, Awaiting a Response
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E